Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 1

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 1
---
 number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

| Large accelerated filer  ☒ |     | Accelerated filer  ☐         |
| Non-accelerated filer  ☐   |     | Smaller reporting company  ☐ |
|                            |     | Emerging growth company  ☐   |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

### EXPLANATORY NOTE
The registration statement contains:

• a base prospectus, which covers the offering, sale and issuance by us of the securities identified above from time to time in one or more offerings; and

• a prospectus supplement which covers the offering, issuance and sale by us of up to a maximum aggregate offering price of $400.0 million of our common stock that may be issued and sold from time to time under an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, as our sales agents. On February 28, 2022,we filed an equity distribution agreement prospectus supplement (the “Prior Equity Distribution Agreement Prospectus”) covering the offering, issuance, and sale by the registrant of up to a maximum aggregate offering price of